Collagenase is a Common Treatment of MCP and PIP Joint Contractures in Dupuytrens Disease
Collagenase Clostridium Histolytic is a Common Treatment of MCP and PIP Joint Contractures in Dupuytren Disease. A 1 to 4 Year Followup Study of 198 Joints
1 other identifier
observational
199
0 countries
N/A
Brief Summary
To evaluate the effect of collagenase clostridium histolyticum treatment at the Department of Orthopaedic surgery at Horsens Regional Hospital after minimum one-year follow-up (FU).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2017
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2017
CompletedFirst Submitted
Initial submission to the registry
October 26, 2017
CompletedFirst Posted
Study publicly available on registry
November 6, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2019
CompletedApril 22, 2020
April 1, 2020
5 months
October 26, 2017
April 20, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Change in extension deficit from baseline to FU in MCP and PIP joints after treatment
Minimum one year after treatment
Interventions
Follow-up of effect of treatment
Eligibility Criteria
All patients who received Xiapex treatment in Horsens from 2013 to May 2016 with a least 1 years of followup.
You may qualify if:
- dupuytrens disease
- xiapex treatment
You may not qualify if:
- \- demens/other psychiatric diseases
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Jeppe Langelead
Related Publications (1)
Hartig-Andreasen C, Schroll L, Lange J. Clostridium histolyticum as first-line treatment of Dupuytren's disease. Dan Med J. 2019 Feb;66(2):A5527.
PMID: 30722822RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Charlotte Hartig-Andreasen, MD, PhD
Regionshospitalet Horsens
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Research secretary
Study Record Dates
First Submitted
October 26, 2017
First Posted
November 6, 2017
Study Start
January 1, 2017
Primary Completion
May 31, 2017
Study Completion
December 31, 2019
Last Updated
April 22, 2020
Record last verified: 2020-04
Data Sharing
- IPD Sharing
- Will not share